IS6310A - Kínasólínafleiður til lækninga - Google Patents

Kínasólínafleiður til lækninga

Info

Publication number
IS6310A
IS6310A IS6310A IS6310A IS6310A IS 6310 A IS6310 A IS 6310A IS 6310 A IS6310 A IS 6310A IS 6310 A IS6310 A IS 6310A IS 6310 A IS6310 A IS 6310A
Authority
IS
Iceland
Prior art keywords
quinazoline derivatives
medicinal purposes
medicinal
purposes
quinazoline
Prior art date
Application number
IS6310A
Other languages
English (en)
Inventor
Austen Mortlock Andrew
John Keen Nicholas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6310A publication Critical patent/IS6310A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS6310A 1999-09-21 2002-03-19 Kínasólínafleiður til lækninga IS6310A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922171.5A GB9922171D0 (en) 1999-09-21 1999-09-21 Chemical compounds
PCT/GB2000/003593 WO2001021597A1 (en) 1999-09-21 2000-09-19 Therapeutic quinazoline derivatives

Publications (1)

Publication Number Publication Date
IS6310A true IS6310A (is) 2002-03-19

Family

ID=10861217

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6310A IS6310A (is) 1999-09-21 2002-03-19 Kínasólínafleiður til lækninga

Country Status (24)

Country Link
US (1) US7235559B1 (is)
EP (1) EP1218355A1 (is)
JP (1) JP2003509500A (is)
KR (1) KR20020030123A (is)
CN (1) CN1391563A (is)
AR (1) AR025735A1 (is)
AU (1) AU762697B2 (is)
BG (1) BG106526A (is)
BR (1) BR0014137A (is)
CA (1) CA2384296A1 (is)
CO (1) CO5200783A1 (is)
CZ (1) CZ20021008A3 (is)
EE (1) EE200200118A (is)
GB (1) GB9922171D0 (is)
HK (1) HK1046685A1 (is)
HU (1) HUP0300205A3 (is)
IL (1) IL148496A0 (is)
IS (1) IS6310A (is)
NO (1) NO20021400L (is)
PL (1) PL354870A1 (is)
SK (1) SK3872002A3 (is)
TR (1) TR200200717T2 (is)
WO (1) WO2001021597A1 (is)
ZA (1) ZA200202232B (is)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2283311C2 (ru) 2000-06-28 2006-09-10 Астразенека Аб Замещенные производные хиназолина и их применение в качестве ингибиторов
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
JP2002293773A (ja) * 2001-03-30 2002-10-09 Sumika Fine Chemicals Co Ltd キナゾリン誘導体の製造方法
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
WO2003035602A1 (fr) * 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
DK1463506T3 (da) 2001-12-24 2010-01-11 Astrazeneca Ab Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser
EP1471910A2 (en) 2002-01-17 2004-11-03 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
KR100942073B1 (ko) * 2002-08-23 2010-02-12 기린 홀딩스 가부시키가이샤 TGF β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056801A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab Quinazoline derivatives
WO2004056812A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
EP1575591A4 (en) * 2002-12-23 2007-09-12 Ariad Pharma Inc HETEROCYCLES AND ITS USE
ATE412657T1 (de) * 2002-12-24 2008-11-15 Astrazeneca Ab Therapeutische quinazolin-derivate
AU2003290313B2 (en) 2002-12-24 2007-05-10 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
MXPA05006920A (es) 2002-12-24 2006-02-10 Astrazeneca Ab Compuestos de quinazolina.
KR20060003351A (ko) 2003-04-16 2006-01-10 아스트라제네카 아베 화합물
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
WO2004108710A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours
WO2004108707A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
WO2004108711A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
CN103664802B (zh) * 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
ES2371383T3 (es) 2003-09-26 2011-12-30 Exelixis, Inc. N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CA2542076C (en) * 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
CA2540342A1 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
ES2315834T3 (es) 2004-02-03 2009-04-01 Astrazeneca Ab Derivados de quinazolina.
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0510980A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina para o tratamento do crescimento anormal de células
BRPI0511132A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina e composição farmacêutica compreendendo os mesmos
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
JP4237242B2 (ja) 2004-10-12 2009-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
ATE421510T1 (de) * 2005-03-28 2009-02-15 Bristol Myers Squibb Co Kompetitive atp-kinasehemmer
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009528336A (ja) * 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キノリン誘導体
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
CN101215274B (zh) * 2007-12-27 2011-05-04 上海北卡医药技术有限公司 N取代吗啉类有机化合物的制备工艺
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
EP2288611B1 (en) 2008-03-20 2013-05-15 Amgen Inc. Aurora kinase modulators and method of use
ES2444128T3 (es) 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
RU2011119478A (ru) 2008-10-14 2012-11-27 Нин Си Соединения и способы применения
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
TW202241853A (zh) 2009-01-16 2022-11-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
JP5583751B2 (ja) * 2009-03-21 2014-09-03 クイ ニング アミノエステル誘導体、その塩、及び使用方法
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
CN103304489B (zh) * 2012-03-16 2015-03-11 中国农业科学院兰州畜牧与兽药研究所 嘧啶苯甲酰胺类化合物及其制备和应用
HUE048498T2 (hu) 2013-09-16 2020-07-28 Astrazeneca Ab Terápiás polimer nanorészecskék és eljárások elõállításukra és alkalmazásukra
US10030004B2 (en) 2014-01-01 2018-07-24 Medivation Technologies Llc Compounds and methods of use
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
EP3184507A1 (en) * 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Preparation of phenyl compounds
EP3570834B1 (en) 2017-01-11 2021-12-22 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
MA49839B1 (fr) 2017-08-07 2022-05-31 Alkermes Inc Inhibiteurs bicycliques de la histone déacétylase
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
EP1162974A1 (en) * 1999-03-19 2001-12-19 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines

Also Published As

Publication number Publication date
AR025735A1 (es) 2002-12-11
JP2003509500A (ja) 2003-03-11
AU762697B2 (en) 2003-07-03
BR0014137A (pt) 2002-05-21
CZ20021008A3 (cs) 2002-06-12
CN1391563A (zh) 2003-01-15
CO5200783A1 (es) 2002-09-27
GB9922171D0 (en) 1999-11-17
HUP0300205A3 (en) 2003-08-28
TR200200717T2 (tr) 2002-06-21
KR20020030123A (ko) 2002-04-22
EP1218355A1 (en) 2002-07-03
US7235559B1 (en) 2007-06-26
WO2001021597A1 (en) 2001-03-29
HUP0300205A2 (en) 2003-05-28
NO20021400D0 (no) 2002-03-20
HK1046685A1 (zh) 2003-01-24
EE200200118A (et) 2003-04-15
SK3872002A3 (en) 2002-12-03
CA2384296A1 (en) 2001-03-29
NO20021400L (no) 2002-05-06
ZA200202232B (en) 2003-08-27
AU7301900A (en) 2001-04-24
BG106526A (en) 2002-10-31
PL354870A1 (en) 2004-03-08
IL148496A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
IS6310A (is) Kínasólínafleiður til lækninga
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
DE60039206D1 (de) Neue Quinazolin-Derivate
NO20015175D0 (no) Farmasöytisk sammensetning
EE200300071A (et) Kinasoliini derivaadid
DE60009747D1 (de) Admantan-derivate
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
ATE293104T1 (de) Thiazolylamid-derivate
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
DK1275397T3 (da) Lægemiddel til lokal anvendelse
ATE257148T1 (de) Propargyletherderivate
NO20022606L (no) Farmasöytiske kombinasjoner
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
NO20014926L (no) Farmasöytiske forbindelser
ATE293592T1 (de) Resorcinderivate
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
FI4488U1 (fi) Farmaseuttinen koostumus
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20016430L (no) Farmasöytisk kompleks
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DK1178984T3 (da) 1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate